Welcome to our dedicated page for Staar Surg SEC filings (Ticker: STAA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
STAAR Surgical Company filings document the regulatory record for a NASDAQ-listed ophthalmic device company focused on phakic IOLs and the EVO family of Implantable Collamer® Lenses. Its reports and exhibits cover operating results, preliminary sales disclosures, shareholder letters, product and market commentary, and clinical or regulatory matters tied to lens-based vision correction.
Recent filings also address proxy and governance disclosure, shareholder voting matters, board and committee composition, director independence, executive appointments and separation arrangements, material agreements, capital-structure disclosure for common stock, and the termination of a previously disclosed merger agreement.
STAAR Surgical Company is asking shareholders to vote at its virtual 2026 annual meeting on June 18, 2026. The proxy seeks approval to elect seven directors, add 3.9 million shares to its Omnibus Equity Incentive Plan, ratify BDO USA as auditor, and approve executive pay on an advisory basis.
The filing details significant recent changes, including termination of an all-cash merger agreement with Alcon, a cooperation agreement with major shareholder Broadwood, board refreshment that added three investor‑aligned directors, and the appointment of interim Co‑CEOs Warren Foust and Deborah Andrews. It also outlines 2026 strategic priorities around expanding EVO lens access, improving profitability through cost and supply‑chain actions, and accelerating innovation, alongside pay‑for‑performance changes such as a 50% PSU / 50% RSU long‑term incentive mix and a redesigned bonus plan funded at 140% for 2025.
BlackRock, Inc. amended a Schedule 13G to report beneficial ownership of 6,507,911 shares of STAAR SURGICAL CO common stock, representing 13.1% of the class as of 03/31/2026.
The filing attributes 6,453,653 shares of sole voting power and lists iShares Core S&P Small-Cap ETF as a holder with more than 5% interest in the issuer’s common stock. The amendment is signed by a Managing Director on 04/24/2026.
Madison Avenue group reports beneficial ownership of 2,854,710 shares of STAAR SURGICAL common stock as of April 20, 2026. The filing states this equals approximately 5.8% of the outstanding common stock based on 49,512,749 shares outstanding as of February 27, 2026. The Schedule 13G lists Madison Avenue International LP and affiliated entities and individuals (including Eli Samaha) as reporting persons with shared voting and dispositive power over the 2,854,710 shares.
STAAR Surgical Company released preliminary results showing strong first quarter 2026 momentum. Net sales for the quarter ended April 3, 2026 are expected to exceed $90 million, up sharply from $42.6 million in the first quarter of 2025, driven mainly by growth in China and continued double-digit growth in the Americas.
The company cites a significantly improved cost structure and expects a meaningful improvement in adjusted EBITDA for the quarter. Management also notes that geopolitical and macroeconomic challenges, particularly in parts of the Middle East, EMEA and APAC, have weighed on sales there and could continue to do so. STAAR plans to report full first quarter 2026 results and file its 10-Q in early May 2026.
STAAR Surgical Co filing: an amended Schedule 13G/A from The Vanguard Group reports 0 shares beneficially owned and 0% of common stock. The filing states Vanguard completed an internal realignment on January 12, 2026 and will report certain subsidiaries separately in reliance on SEC Release No. 34-39538.
The filing lists Vanguard's address and is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
ANDREWS DEBORAH J reported acquisition or exercise transactions in this Form 4 filing.
STAAR Surgical granted Interim Co-CEO and CFO Deborah J. Andrews 39,809 restricted stock units (RSUs) on March 13, 2026 as an annual equity award. Each RSU represents one share of common stock and vests in three equal installments through March 13, 2029.
STAAR Surgical’s interim co-CEO and president & COO Warren Foust reported equity compensation activity, mainly from restricted stock units (RSUs). On March 13, 2026, he received a grant of 45,117 RSUs, which will vest in three equal annual installments starting in 2027.
On March 12 and 14, 2026, previously granted RSUs vested and were converted into common stock through option code M transactions, totaling 37,500 shares acquired. Following these events, he directly held 63,588 shares of common stock and 45,117 RSUs subject to future vesting.
STAAR Surgical’s Chief Development Officer Magda Michna reported several equity compensation events. On March 13, 2026, she received a grant of 33,838 restricted stock units (RSUs), which are scheduled to vest in three equal tranches in 2027, 2028, and 2029.
On March 12 and 14, 2026, previously granted RSUs vested and were converted into a total of 23,773 shares of common stock. In connection with these vestings, the company withheld 2,216 shares at $18.39 and 6,313 shares at $18.84 to cover tax obligations, which is recorded as a disposition but not an open‑market sale. Following these transactions, Michna directly holds 29,668 shares of common stock, along with RSUs that remain subject to future vesting.
Broadwood Partners, Broadwood Capital and related individuals updated their ownership in STAAR Surgical Company’s common stock. Broadwood Partners and Broadwood Capital each report beneficial ownership of 16,123,842 shares, representing 32.6% of the 49,512,749 shares outstanding. Neal C. Bradsher may be deemed to beneficially own 16,149,742 shares, also 32.6%, through personal holdings and Broadwood Partners, while Richard T. LeBuhn reports 21,286 shares, or 0.0% of the class.
The amendment primarily reflects changes in beneficial ownership percentages and the fact that LeBuhn will cease to be a reporting person following this filing. The group continues to review its investment, may buy or sell shares over time, and remains in contact with management and other shareholders about ways to create additional shareholder value, but discloses no specific current plans for major corporate actions.